25 XP   0   0   10

Lyell Immunopharma Inc
Buy, Hold or Sell?

Let's analyse Lyell together

PenkeI guess you are interested in Lyell Immunopharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Lyell Immunopharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Lyell Immunopharma Inc

I send you an email if I find something interesting about Lyell Immunopharma Inc.

Quick analysis of Lyell (30 sec.)










What can you expect buying and holding a share of Lyell? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.58
Expected worth in 1 year
$1.88
How sure are you?
18.8%

+ What do you gain per year?

Total Gains per Share
$-0.70
Return On Investment
-31.5%

For what price can you sell your share?

Current Price per Share
$2.23
Expected price per share
$1.84 - $3.41
How sure are you?
50%

1. Valuation of Lyell (5 min.)




Live pricePrice per Share (EOD)

$2.23

Intrinsic Value Per Share

$-3.44 - $-3.83

Total Value Per Share

$-0.86 - $-1.25

2. Growth of Lyell (5 min.)




Is Lyell growing?

Current yearPrevious yearGrowGrow %
How rich?$654.9m$850.6m-$132.3m-18.4%

How much money is Lyell making?

Current yearPrevious yearGrowGrow %
Making money-$75m-$43.6m-$31.3m-41.8%
Net Profit Margin-262,810.4%-619,084.2%--

How much money comes from the company's main activities?

3. Financial Health of Lyell (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#84 / 1016

Most Revenue
#672 / 1016

Most Profit
#943 / 1016

Most Efficient
#1011 / 1016

What can you expect buying and holding a share of Lyell? (5 min.)

Welcome investor! Lyell's management wants to use your money to grow the business. In return you get a share of Lyell.

What can you expect buying and holding a share of Lyell?

First you should know what it really means to hold a share of Lyell. And how you can make/lose money.

Speculation

The Price per Share of Lyell is $2.23. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lyell.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lyell, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.58. Based on the TTM, the Book Value Change Per Share is $-0.18 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lyell.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.21-9.3%-0.23-10.4%-0.18-8.1%-0.22-9.7%-0.22-9.7%
Usd Book Value Change Per Share-0.17-7.5%-0.18-7.9%-0.09-4.3%0.167.2%0.167.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.17-7.5%-0.18-7.9%-0.09-4.3%0.167.2%0.167.2%
Usd Price Per Share1.94-2.24-5.59-4.38-4.38-
Price to Earnings Ratio-2.33--2.39--12.25--6.26--6.26-
Price-to-Total Gains Ratio-11.57--12.60--31.00--27.56--27.56-
Price to Book Ratio0.75-0.79-1.67-1.24-1.24-
Price-to-Total Gains Ratio-11.57--12.60--31.00--27.56--27.56-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.23
Number of shares448
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.180.16
Usd Total Gains Per Share-0.180.16
Gains per Quarter (448 shares)-78.5972.17
Gains per Year (448 shares)-314.36288.69
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-314-3240289279
20-629-6380577568
30-943-9520866857
40-1257-1266011551146
50-1572-1580014431435
60-1886-1894017321724
70-2201-2208020212013
80-2515-2522023102302
90-2829-2836025982591
100-3144-3150028872880

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.016.00.00.0%0.016.00.00.0%0.016.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%3.010.03.018.8%3.010.03.018.8%3.010.03.018.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.016.00.0%0.00.016.00.0%0.00.016.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%3.010.03.018.8%3.010.03.018.8%3.010.03.018.8%

Fundamentals of Lyell

About Lyell Immunopharma Inc

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-04-11 13:55:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Lyell Immunopharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Lyell earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Lyell to the Biotechnology industry mean.
  • A Net Profit Margin of -407,153.8% means that $-4,071.54 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lyell Immunopharma Inc:

  • The MRQ is -407,153.8%. The company is making a huge loss. -2
  • The TTM is -262,810.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-407,153.8%TTM-262,810.4%-144,343.4%
TTM-262,810.4%YOY-619,084.2%+356,273.8%
TTM-262,810.4%5Y-221,720.4%-41,090.0%
5Y-221,720.4%10Y-221,720.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-407,153.8%-199.6%-406,954.2%
TTM-262,810.4%-213.0%-262,597.4%
YOY-619,084.2%-279.3%-618,804.9%
5Y-221,720.4%-438.4%-221,282.0%
10Y-221,720.4%-605.5%-221,114.9%
1.1.2. Return on Assets

Shows how efficient Lyell is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Lyell to the Biotechnology industry mean.
  • -7.1% Return on Assets means that Lyell generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lyell Immunopharma Inc:

  • The MRQ is -7.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.1%TTM-9.0%+2.0%
TTM-9.0%YOY-4.3%-4.8%
TTM-9.0%5Y-5.0%-4.0%
5Y-5.0%10Y-5.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.1%-13.5%+6.4%
TTM-9.0%-12.9%+3.9%
YOY-4.3%-11.8%+7.5%
5Y-5.0%-14.1%+9.1%
10Y-5.0%-16.0%+11.0%
1.1.3. Return on Equity

Shows how efficient Lyell is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Lyell to the Biotechnology industry mean.
  • -8.1% Return on Equity means Lyell generated $-0.08 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lyell Immunopharma Inc:

  • The MRQ is -8.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -10.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.1%TTM-10.2%+2.2%
TTM-10.2%YOY-5.1%-5.1%
TTM-10.2%5Y-5.9%-4.3%
5Y-5.9%10Y-5.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.1%-16.9%+8.8%
TTM-10.2%-16.1%+5.9%
YOY-5.1%-15.1%+10.0%
5Y-5.9%-19.9%+14.0%
10Y-5.9%-20.9%+15.0%

1.2. Operating Efficiency of Lyell Immunopharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Lyell is operating .

  • Measures how much profit Lyell makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Lyell to the Biotechnology industry mean.
  • An Operating Margin of -460,230.8% means the company generated $-4,602.31  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lyell Immunopharma Inc:

  • The MRQ is -460,230.8%. The company is operating very inefficient. -2
  • The TTM is -256,473.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-460,230.8%TTM-256,473.4%-203,757.4%
TTM-256,473.4%YOY-556,772.2%+300,298.9%
TTM-256,473.4%5Y-204,510.8%-51,962.6%
5Y-204,510.8%10Y-204,510.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-460,230.8%-295.1%-459,935.7%
TTM-256,473.4%-225.8%-256,247.6%
YOY-556,772.2%-288.4%-556,483.8%
5Y-204,510.8%-477.4%-204,033.4%
10Y-204,510.8%-625.6%-203,885.2%
1.2.2. Operating Ratio

Measures how efficient Lyell is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 4,603.31 means that the operating costs are $4,603.31 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Lyell Immunopharma Inc:

  • The MRQ is 4,603.308. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2,705.201. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4,603.308TTM2,705.201+1,898.107
TTM2,705.201YOY5,940.199-3,234.998
TTM2,705.2015Y2,173.843+531.357
5Y2,173.84310Y2,173.8430.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4,603.3083.090+4,600.218
TTM2,705.2013.264+2,701.937
YOY5,940.1993.783+5,936.416
5Y2,173.8435.679+2,168.164
10Y2,173.8437.894+2,165.949

1.3. Liquidity of Lyell Immunopharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Lyell is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 16.07 means the company has $16.07 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Lyell Immunopharma Inc:

  • The MRQ is 16.069. The company is very able to pay all its short-term debts. +2
  • The TTM is 17.678. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ16.069TTM17.678-1.609
TTM17.678YOY14.742+2.936
TTM17.6785Y11.882+5.797
5Y11.88210Y11.8820.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.0693.914+12.155
TTM17.6784.220+13.458
YOY14.7425.388+9.354
5Y11.8826.045+5.837
10Y11.8826.406+5.476
1.3.2. Quick Ratio

Measures if Lyell is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Lyell to the Biotechnology industry mean.
  • A Quick Ratio of 27.43 means the company can pay off $27.43 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lyell Immunopharma Inc:

  • The MRQ is 27.428. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 29.113. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ27.428TTM29.113-1.684
TTM29.113YOY25.186+3.927
TTM29.1135Y19.219+9.894
5Y19.21910Y19.2190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ27.4283.572+23.856
TTM29.1133.998+25.115
YOY25.1865.390+19.796
5Y19.2195.969+13.250
10Y19.2196.287+12.932

1.4. Solvency of Lyell Immunopharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Lyell assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Lyell to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.13 means that Lyell assets are financed with 12.7% credit (debt) and the remaining percentage (100% - 12.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Lyell Immunopharma Inc:

  • The MRQ is 0.127. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.119. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.127TTM0.119+0.008
TTM0.119YOY0.150-0.031
TTM0.1195Y0.127-0.008
5Y0.12710Y0.1270.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1270.336-0.209
TTM0.1190.334-0.215
YOY0.1500.269-0.119
5Y0.1270.366-0.239
10Y0.1270.390-0.263
1.4.2. Debt to Equity Ratio

Measures if Lyell is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Lyell to the Biotechnology industry mean.
  • A Debt to Equity ratio of 14.5% means that company has $0.15 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lyell Immunopharma Inc:

  • The MRQ is 0.145. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.135. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.145TTM0.135+0.010
TTM0.135YOY0.178-0.042
TTM0.1355Y0.153-0.017
5Y0.15310Y0.1530.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1450.382-0.237
TTM0.1350.396-0.261
YOY0.1780.335-0.157
5Y0.1530.434-0.281
10Y0.1530.465-0.312

2. Market Valuation of Lyell Immunopharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Lyell generates.

  • Above 15 is considered overpriced but always compare Lyell to the Biotechnology industry mean.
  • A PE ratio of -2.33 means the investor is paying $-2.33 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lyell Immunopharma Inc:

  • The EOD is -2.676. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.328. Based on the earnings, the company is expensive. -2
  • The TTM is -2.391. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.676MRQ-2.328-0.348
MRQ-2.328TTM-2.391+0.063
TTM-2.391YOY-12.247+9.856
TTM-2.3915Y-6.259+3.868
5Y-6.25910Y-6.2590.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.676-2.259-0.417
MRQ-2.328-2.569+0.241
TTM-2.391-2.664+0.273
YOY-12.247-4.120-8.127
5Y-6.259-6.258-0.001
10Y-6.259-6.171-0.088
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lyell Immunopharma Inc:

  • The EOD is -3.484. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.031. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.419. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.484MRQ-3.031-0.453
MRQ-3.031TTM-3.419+0.388
TTM-3.419YOY-7.550+4.131
TTM-3.4195Y-6.136+2.718
5Y-6.13610Y-6.1360.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.484-2.924-0.560
MRQ-3.031-3.246+0.215
TTM-3.419-3.488+0.069
YOY-7.550-5.620-1.930
5Y-6.136-8.315+2.179
10Y-6.136-8.826+2.690
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Lyell is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.75 means the investor is paying $0.75 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Lyell Immunopharma Inc:

  • The EOD is 0.865. Based on the equity, the company is cheap. +2
  • The MRQ is 0.753. Based on the equity, the company is cheap. +2
  • The TTM is 0.787. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.865MRQ0.753+0.113
MRQ0.753TTM0.787-0.035
TTM0.787YOY1.674-0.886
TTM0.7875Y1.238-0.451
5Y1.23810Y1.2380.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.8651.851-0.986
MRQ0.7532.090-1.337
TTM0.7872.095-1.308
YOY1.6742.844-1.170
5Y1.2383.466-2.228
10Y1.2383.815-2.577
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Lyell Immunopharma Inc.

3.1. Institutions holding Lyell Immunopharma Inc

Institutions are holding 72.877% of the shares of Lyell Immunopharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31MWG Management Ltd.7.934932.90362016233200
2023-12-31Orland Properties Ltd5.940314.29641509396900
2023-12-31BlackRock Inc5.62870.0007143022208819786.572
2023-12-31Vanguard Group Inc5.35390.000613604027-3305693-19.5491
2023-12-31Foresite Capital Management IV, LLC3.27638.16218325000-459813-5.2342
2023-12-31Wuxi AppTec Co Ltd3.219541.1509818067881806780
2023-12-31T. Rowe Price Associates, Inc.2.61270.00176638883-47314-0.7076
2023-12-31Alphabet Inc2.30820.5276586512500
2023-12-31Geode Capital Management, LLC1.54960.000839373502808677.6813
2023-12-31State Street Corporation1.39280.00033539086-3271342-48.0343
2023-09-30SC China Holding Ltd1.19880.4802304599700
2023-12-31FMR Inc1.09750.00042788727-58699-2.0615
2023-12-31MIC Capital Management UK LLP0.6850.6551174056900
2023-12-31Bank of America Corp0.65350.00031660589932492128.0725
2023-12-31Northern Trust Corp0.58070.00051475509-7669-0.5171
2023-12-31Massachusetts Financial Services Company0.53310.00091354678-8512-0.6244
2023-12-31Charles Schwab Investment Management Inc0.49860.00061266863161521.2914
2023-12-31Goldman Sachs Group Inc0.49410.00021255390717773133.5101
2023-12-31TD Asset Management Inc0.36060.001891623200
2023-12-31Millennium Management LLC0.35380.0008899017703502359.82
Total 45.672698.1855116052241+4554400+3.9%

3.2. Funds holding Lyell Immunopharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.28630.00115809285-364981-5.9113
2023-12-31T. Rowe Price Health Sciences1.98580.06655045778-104830-2.0353
2024-03-28iShares Russell 2000 ETF1.68530.0146428226020640.0482
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.92480.00672349925217280.9333
2024-02-29Vanguard Small Cap Index0.8950.00472274159205460.9117
2024-01-31Fidelity Small Cap Index0.69120.0131756367154270.8861
2024-03-28iShares Russell 2000 Value ETF0.63960.02891625133-1031-0.0634
2024-02-29Vanguard Small Cap Growth Index Inv0.50240.01071276648212231.6905
2024-02-29Fidelity Growth Compy Commingled Pl O0.4830.0046122723900
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.40150.0071102016350000.4925
2024-02-29Fidelity Growth Company Fund0.35110.004489202600
2024-02-29Fidelity Extended Market Index0.350.0068889262-4309-0.4822
2024-01-31Invenomic Institutional0.3490.11338867318867310
2024-03-28iShares Biotechnology ETF0.33910.0252861610-37518-4.1727
2024-03-29Schwab US Small-Cap ETF™0.2960.009875221000
2024-02-29MFS New Discovery I0.26630.080367662700
2024-02-29Vanguard Russell 2000 ETF0.24820.0193630574493858.4972
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.24370.014261924200
2023-12-31NT R2000 Value Index Fund - NL0.19560.0255497138-13780-2.6971
2023-12-31NT R2000 Index Fund - NL0.19430.0132493614-13018-2.5695
Total 13.32820.469933865991+482637+1.4%

3.3. Insider Transactions

Insiders are holding 15.59% of the shares of Lyell Immunopharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-09-23Richard KlausnerSELL111006.4

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Lyell Immunopharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.168-0.175+5%-0.095-43%0.161-204%0.161-204%
Book Value Per Share--2.5782.827-9%3.348-23%2.610-1%2.610-1%
Current Ratio--16.06917.678-9%14.742+9%11.882+35%11.882+35%
Debt To Asset Ratio--0.1270.119+6%0.150-16%0.1270%0.1270%
Debt To Equity Ratio--0.1450.135+7%0.178-18%0.153-5%0.153-5%
Dividend Per Share----0%-0%-0%-0%
Eps---0.208-0.231+11%-0.180-14%-0.215+3%-0.215+3%
Free Cash Flow Per Share---0.160-0.164+2%-0.191+19%-0.188+17%-0.188+17%
Free Cash Flow To Equity Per Share---0.157-0.162+3%-0.180+15%0.031-606%0.031-606%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---3.827--------
Intrinsic Value_10Y_min---3.440--------
Intrinsic Value_1Y_max---0.676--------
Intrinsic Value_1Y_min---0.664--------
Intrinsic Value_3Y_max---1.808--------
Intrinsic Value_3Y_min---1.730--------
Intrinsic Value_5Y_max---2.671--------
Intrinsic Value_5Y_min---2.498--------
Market Cap566634080.000+13%492946240.000568539800.000-13%1421031880.000-65%1113258100.000-56%1113258100.000-56%
Net Profit Margin---4071.538-2628.104-35%-6190.842+52%-2217.204-46%-2217.204-46%
Operating Margin---4602.308-2564.734-44%-5567.722+21%-2045.108-56%-2045.108-56%
Operating Ratio--4603.3082705.201+70%5940.199-23%2173.843+112%2173.843+112%
Pb Ratio0.865+13%0.7530.787-4%1.674-55%1.238-39%1.238-39%
Pe Ratio-2.676-15%-2.328-2.391+3%-12.247+426%-6.259+169%-6.259+169%
Price Per Share2.230+13%1.9402.238-13%5.593-65%4.381-56%4.381-56%
Price To Free Cash Flow Ratio-3.484-15%-3.031-3.419+13%-7.550+149%-6.136+102%-6.136+102%
Price To Total Gains Ratio-13.295-15%-11.566-12.602+9%-31.001+168%-27.558+138%-27.558+138%
Quick Ratio--27.42829.113-6%25.186+9%19.219+43%19.219+43%
Return On Assets---0.071-0.090+28%-0.043-39%-0.050-29%-0.050-29%
Return On Equity---0.081-0.102+27%-0.051-37%-0.059-26%-0.059-26%
Total Gains Per Share---0.168-0.175+5%-0.095-43%0.161-204%0.161-204%
Usd Book Value--654952000.000718301500.000-9%850642250.000-23%663084437.500-1%663084437.500-1%
Usd Book Value Change Per Share---0.168-0.175+5%-0.095-43%0.161-204%0.161-204%
Usd Book Value Per Share--2.5782.827-9%3.348-23%2.610-1%2.610-1%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.208-0.231+11%-0.180-14%-0.215+3%-0.215+3%
Usd Free Cash Flow---40660000.000-41595000.000+2%-48457750.000+19%-47769937.500+17%-47769937.500+17%
Usd Free Cash Flow Per Share---0.160-0.164+2%-0.191+19%-0.188+17%-0.188+17%
Usd Free Cash Flow To Equity Per Share---0.157-0.162+3%-0.180+15%0.031-606%0.031-606%
Usd Market Cap566634080.000+13%492946240.000568539800.000-13%1421031880.000-65%1113258100.000-56%1113258100.000-56%
Usd Price Per Share2.230+13%1.9402.238-13%5.593-65%4.381-56%4.381-56%
Usd Profit---52930000.000-75075750.000+42%-43682349.250-17%-58107712.313+10%-58107712.313+10%
Usd Revenue--13000.00032500.000-60%9086346.500-100%3430086.625-100%3430086.625-100%
Usd Total Gains Per Share---0.168-0.175+5%-0.095-43%0.161-204%0.161-204%
 EOD+5 -3MRQTTM+17 -16YOY+15 -185Y+13 -2010Y+13 -20

4.2. Fundamental Score

Let's check the fundamental score of Lyell Immunopharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.676
Price to Book Ratio (EOD)Between0-10.865
Net Profit Margin (MRQ)Greater than0-4,071.538
Operating Margin (MRQ)Greater than0-4,602.308
Quick Ratio (MRQ)Greater than127.428
Current Ratio (MRQ)Greater than116.069
Debt to Asset Ratio (MRQ)Less than10.127
Debt to Equity Ratio (MRQ)Less than10.145
Return on Equity (MRQ)Greater than0.15-0.081
Return on Assets (MRQ)Greater than0.05-0.071
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Lyell Immunopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.310
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets750,029
Total Liabilities95,077
Total Stockholder Equity654,952
 As reported
Total Liabilities 95,077
Total Stockholder Equity+ 654,952
Total Assets = 750,029

Assets

Total Assets750,029
Total Current Assets554,686
Long-term Assets195,343
Total Current Assets
Cash And Cash Equivalents 145,647
Short-term Investments 400,576
Other Current Assets 8,463
Total Current Assets  (as reported)554,686
Total Current Assets  (calculated)554,686
+/-0
Long-term Assets
Property Plant Equipment 142,317
Long Term Investments 48,507
Long-term Assets Other 4,519
Long-term Assets  (as reported)195,343
Long-term Assets  (calculated)195,343
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities34,519
Long-term Liabilities60,558
Total Stockholder Equity654,952
Total Current Liabilities
Short-term Debt 6,273
Accounts payable 4,817
Other Current Liabilities 3,069
Total Current Liabilities  (as reported)34,519
Total Current Liabilities  (calculated)14,159
+/- 20,360
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt56,894
Long-term Liabilities Other 3,664
Long-term Liabilities  (as reported)60,558
Long-term Liabilities  (calculated)60,558
+/-0
Total Stockholder Equity
Common Stock25
Retained Earnings -1,002,112
Accumulated Other Comprehensive Income -94
Other Stockholders Equity 1,657,133
Total Stockholder Equity (as reported)654,952
Total Stockholder Equity (calculated)654,952
+/-0
Other
Capital Stock25
Cash and Short Term Investments 546,223
Common Stock Shares Outstanding 253,086
Current Deferred Revenue20,360
Liabilities and Stockholders Equity 750,029
Net Debt -82,480
Net Invested Capital 654,952
Net Working Capital 520,167
Property Plant and Equipment Gross 193,964
Short Long Term Debt Total 63,167



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
908,280
877,189
1,229,867
1,198,334
1,127,406
1,072,103
1,021,674
977,269
937,561
880,450
835,354
794,989
750,029
750,029794,989835,354880,450937,561977,2691,021,6741,072,1031,127,4061,198,3341,229,867877,189908,280000
   > Total Current Assets 
0
0
0
617,547
609,735
834,840
631,147
626,286
625,705
666,778
659,745
651,295
624,398
606,410
586,854
554,686
554,686586,854606,410624,398651,295659,745666,778625,705626,286631,147834,840609,735617,547000
       Cash And Cash Equivalents 
0
0
0
140,406
244,370
564,441
393,504
293,828
222,596
205,739
116,311
123,554
109,426
224,372
286,214
145,647
145,647286,214224,372109,426123,554116,311205,739222,596293,828393,504564,441244,370140,406000
       Short-term Investments 
0
0
0
472,213
360,563
260,082
225,417
320,966
391,316
449,825
531,821
516,598
503,343
371,376
289,217
400,576
400,576289,217371,376503,343516,598531,821449,825391,316320,966225,417260,082360,563472,213000
       Other Current Assets 
0
0
0
4,928
4,802
10,317
12,226
11,492
11,793
11,214
11,613
11,143
11,629
10,662
11,423
8,463
8,46311,42310,66211,62911,14311,61311,21411,79311,49212,22610,3174,8024,928000
   > Long-term Assets 
0
0
0
290,733
267,454
395,027
567,187
501,120
446,398
354,896
317,524
286,266
256,052
228,944
208,135
195,343
195,343208,135228,944256,052286,266317,524354,896446,398501,120567,187395,027267,454290,733000
       Property Plant Equipment 
0
0
0
124,055
144,874
158,061
163,093
166,639
171,432
172,466
169,811
166,265
160,990
155,189
148,699
142,317
142,317148,699155,189160,990166,265169,811172,466171,432166,639163,093158,061144,874124,055000
       Long Term Investments 
0
0
0
163,443
118,652
233,709
400,959
330,532
271,119
178,439
144,520
115,041
90,179
68,953
54,730
48,507
48,50754,73068,95390,179115,041144,520178,439271,119330,532400,959233,709118,652163,443000
       Other Assets 
0
0
0
0
3,928
3,257
3,135
3,949
3,847
3,991
3,193
4,960
0
4,802
0
0
004,80204,9603,1933,9913,8473,9493,1353,2573,9280000
> Total Liabilities 
0
0
0
189,840
200,269
207,912
211,860
197,619
190,854
153,632
157,243
104,309
96,624
98,499
97,416
95,077
95,07797,41698,49996,624104,309157,243153,632190,854197,619211,860207,912200,269189,840000
   > Total Current Liabilities 
0
0
0
49,285
56,812
63,663
59,281
46,738
41,055
50,291
51,217
37,028
30,797
34,390
35,064
34,519
34,51935,06434,39030,79737,02851,21750,29141,05546,73859,28163,66356,81249,285000
       Short-term Debt 
0
0
0
3,617
26,035
25,568
25,058
1,169
0
0
0
4,534
4,810
5,853
6,061
6,273
6,2736,0615,8534,8104,5340001,16925,05825,56826,0353,617000
       Accounts payable 
0
0
0
9,396
7,121
4,863
3,526
3,207
6,510
4,247
4,795
3,917
5,733
5,805
4,365
4,817
4,8174,3655,8055,7333,9174,7954,2476,5103,2073,5264,8637,1219,396000
       Other Current Liabilities 
0
0
0
30,177
15,740
25,006
25,116
37,374
28,321
30,618
35,231
6,708
25,064
28,585
30,699
3,069
3,06930,69928,58525,0646,70835,23130,61828,32137,37425,11625,00615,74030,177000
   > Long-term Liabilities 
0
0
0
140,555
143,457
144,249
152,579
150,881
149,799
103,341
106,026
67,281
65,827
64,109
62,352
60,558
60,55862,35264,10965,82767,281106,026103,341149,799150,881152,579144,249143,457140,555000
       Other Liabilities 
0
0
0
0
85,701
82,778
86,895
84,231
82,324
37,267
41,390
4,113
0
3,888
0
0
003,88804,11341,39037,26782,32484,23186,89582,77885,7010000
> Total Stockholder Equity
0
0
0
718,440
676,920
1,021,955
986,474
929,787
881,249
868,042
820,026
833,252
783,826
736,855
697,573
654,952
654,952697,573736,855783,826833,252820,026868,042881,249929,787986,4741,021,955676,920718,440000
   Common Stock
0
0
0
2
2
24
24
24
25
25
25
25
25
25
25
25
252525252525252524242422000
   Retained Earnings Total Equity00-898,329-834,4390-759,083-688,829-652,506-584,362-500,656-451,78100000
   Accumulated Other Comprehensive Income 
0
0
0
256
163
73
-65
-1,623
-6,600
-8,351
-9,996
-7,599
-3,879
-2,379
-1,181
-94
-94-1,181-2,379-3,879-7,599-9,996-8,351-6,600-1,623-6573163256000
   Capital Surplus 
0
0
0
0
0
1,473,639
1,487,171
1,515,748
1,540,330
1,565,197
1,589,080
0
1,622,119
1,637,538
0
0
001,637,5381,622,11901,589,0801,565,1971,540,3301,515,7481,487,1711,473,63900000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
0
0
0
41,357
54,973
243,772
288,837
1,515,748
1,540,330
1,565,197
1,589,080
1,608,306
1,622,119
1,637,538
1,647,911
1,657,133
1,657,1331,647,9111,637,5381,622,1191,608,3061,589,0801,565,1971,540,3301,515,748288,837243,77254,97341,357000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue130
Cost of Revenue-20,250
Gross Profit-20,120-20,120
 
Operating Income (+$)
Gross Profit-20,120
Operating Expense-247,138
Operating Income-247,008-267,258
 
Operating Expense (+$)
Research Development182,945
Selling General Administrative66,983
Selling And Marketing Expenses0
Operating Expense247,138249,928
 
Net Interest Income (+$)
Interest Income23,453
Interest Expense-0
Other Finance Cost-0
Net Interest Income23,453
 
Pretax Income (+$)
Operating Income-247,008
Net Interest Income23,453
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-234,632-235,931
EBIT - interestExpense = -234,085
-245,162
-234,632
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-234,085-234,632
Earnings Before Interest and Taxes (EBITDA)-213,835
 
After tax Income (+$)
Income Before Tax-234,632
Tax Provision-0
Net Income From Continuing Ops-234,632-234,632
Net Income-234,632
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses247,138
Total Other Income/Expenses Net-11,077-23,453
 

Technical Analysis of Lyell
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lyell. The general trend of Lyell is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lyell's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lyell Immunopharma Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 3.2556 < 3.36 < 3.41.

The bearish price targets are: 2.28 > 2.01 > 1.84.

Tweet this
Lyell Immunopharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lyell Immunopharma Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lyell Immunopharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lyell Immunopharma Inc.

Lyell Immunopharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartLyell Immunopharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lyell Immunopharma Inc. The current adx is .

Lyell Immunopharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lyell Immunopharma Inc.

Lyell Immunopharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lyell Immunopharma Inc.

Lyell Immunopharma Inc Daily Relative Strength Index (RSI) ChartLyell Immunopharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lyell Immunopharma Inc.

Lyell Immunopharma Inc Daily Stochastic Oscillator ChartLyell Immunopharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lyell Immunopharma Inc.

Lyell Immunopharma Inc Daily Commodity Channel Index (CCI) ChartLyell Immunopharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lyell Immunopharma Inc.

Lyell Immunopharma Inc Daily Chande Momentum Oscillator (CMO) ChartLyell Immunopharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lyell Immunopharma Inc.

Lyell Immunopharma Inc Daily Williams %R ChartLyell Immunopharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Lyell Immunopharma Inc.

Lyell Immunopharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lyell Immunopharma Inc.

Lyell Immunopharma Inc Daily Average True Range (ATR) ChartLyell Immunopharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lyell Immunopharma Inc.

Lyell Immunopharma Inc Daily On-Balance Volume (OBV) ChartLyell Immunopharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lyell Immunopharma Inc.

Lyell Immunopharma Inc Daily Money Flow Index (MFI) ChartLyell Immunopharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lyell Immunopharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-02BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Lyell Immunopharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lyell Immunopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.310
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Lyell with someone you think should read this too:
  • Are you bullish or bearish on Lyell? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lyell? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lyell Immunopharma Inc

I send you an email if I find something interesting about Lyell Immunopharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Lyell Immunopharma Inc.

Receive notifications about Lyell Immunopharma Inc in your mailbox!